AstraZeneca ' s Imfinzi Gets Speedy FDA Review for Small Cell Lung Cancer AstraZeneca ' s Imfinzi Gets Speedy FDA Review for Small Cell Lung Cancer
British drugmaker AstraZeneca Plc said on Friday its immunotherapy cancer treatment Imfinzi (durvalumab) has been granted a speedy review by the U.S. medicines watchdog for the treatment of a particularly aggressive type of lung cancer.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
More News: Allergy | Allergy & Immunology | AstraZeneca | Cancer | Cancer & Oncology | Hematology | Immunotherapy | Lung Cancer | UK Health